Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) Target Price at $9.17

Cognition Therapeutics, Inc. (NASDAQ:CGTXGet Free Report) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $9.17.

CGTX has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target on shares of Cognition Therapeutics in a report on Wednesday, March 27th. B. Riley reaffirmed a “buy” rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Thursday, March 28th. HC Wainwright assumed coverage on Cognition Therapeutics in a research note on Wednesday, May 29th. They set a “buy” rating and a $10.00 price objective on the stock. Rodman & Renshaw reissued a “buy” rating and set a $14.00 price target on shares of Cognition Therapeutics in a report on Tuesday. Finally, Chardan Capital initiated coverage on shares of Cognition Therapeutics in a research report on Thursday, June 6th. They set a “buy” rating and a $11.00 price target on the stock.

Read Our Latest Analysis on Cognition Therapeutics

Institutional Investors Weigh In On Cognition Therapeutics

Large investors have recently made changes to their positions in the company. Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics in the 1st quarter worth $47,000. Sigma Planning Corp purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $53,000. Levin Capital Strategies L.P. acquired a new position in Cognition Therapeutics in the first quarter valued at approximately $55,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Cognition Therapeutics during the fourth quarter worth about $102,000. Finally, Twin Focus Capital Partners LLC acquired a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $173,000. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Stock Down 2.7 %

CGTX stock opened at $1.77 on Tuesday. Cognition Therapeutics has a 52 week low of $0.90 and a 52 week high of $2.95. The business has a fifty day simple moving average of $2.00 and a 200-day simple moving average of $2.00. The company has a market cap of $70.91 million, a price-to-earnings ratio of -1.92 and a beta of 1.47.

Cognition Therapeutics (NASDAQ:CGTXGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, analysts expect that Cognition Therapeutics will post -0.97 earnings per share for the current fiscal year.

Cognition Therapeutics Company Profile

(Get Free Report

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

Featured Articles

Analyst Recommendations for Cognition Therapeutics (NASDAQ:CGTX)

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.